1.
Chandra S, Kurwale N, Tripathi M, Banerjee J. Epileptogenic networks and drug-resistant epilepsy: Present and future perspectives of epilepsy research-Utility for the epileptologist and the epilepsy surgeon. Ann Indian Acad Neur. 2014; 17(5): 134[DOI]
2.
Kalviainen R,
Ansakorpi H,
Flander S,
Immonen A,
Keranen T,
Kivisto J,
et al.
[Update on Current Care Guideline: epilepsies (adult]. Duodecim. 2014; 130(7): 748-9[PubMed]
3.
Franchi C, Giussani G, Messina P, Montesano M, Romi S, Nobili A. Validation of healthcare administrative data for the diagnosis of epilepsy. J Epidemiol Community Health. 2013; 67(12)[DOI]
4.
Wiebe S. Definition of drug-resistant epilepsy: Is it evidence based? Epilepsia. 2013; 54: 9-12[DOI]
5.
Weaver DF, Pohlmann-Eden B. Pharmacoresistant epilepsy: Unmet needs in solving the puzzle(s). Epilepsia. 2013; 54: 80-5[DOI]
6.
Hao X, Goldberg D, Kelly K, Stephen L, Kwan P, Brodie MJ. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013; 29(1): 4-6[DOI][PubMed]
7.
Gregory JK, Broomall EM. Teaching Video NeuroImages: Reading epilepsy: A seizure in a thousand words (or less). Neurology. 2013; 81(13)[DOI]
8.
Cecen GS, Gulabi D, Oltulu I, Onay T. Generalized epileptic seizure in an adolescent idiopathic scoliosis (AIS) patient with syringomyelia after deformity correction surgery. Int J Surg Case Rep. 2013; 4(8): 740-3[DOI]
9.
Lasoń W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep. 2013; 65(4): 787-801[DOI]
10.
Tolou Ghamari Z. Antiepileptic Drugs (AEDs) Polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett . 2012; 6(3): 207-12
11.
Tolou-Ghamari Z, Najafi MR, Habibabadi JM, Zare M. Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics. Int J Prev Med. 2013; 4-6[PubMed]
12.
Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy. Int J Prev Med. 2013; 4-7[PubMed]
13.
Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013; 18-5[PubMed]
14.
French JA, Faught E. Rational polytherapy. Epilepsia. 2009; 50: 63-8[DOI]
15.
Guberman A. Monotherapy or polytherapy for epilepsy? . Can J Neurol Sci. 1998; 25(4)-8
16.
Arroyo S, Perucca E. Translating monotherapy trials into clinical practice: a look into the abyss. Epilepsy Behav. 2003; 4(5): 457-63[DOI]
17.
Glauser T,
Ben-Menachem E,
Bourgeois B,
Cnaan A,
Chadwick D,
Guerreiro C,
et al.
ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia. 2006; 47(7): 1094-120[DOI]
18.
Macdonald RL, Kelly KM. Antiepileptic Drug Mechanisms of Action. Epilepsia. 1995; 36[DOI]
19.
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of Action. Epilepsia. 2000; 41: 3-9[DOI]
20.
Luszczki JJ,
Czuczwar M,
Kis J,
Krysa J,
Pasztelan I,
Swiader M,
et al.
Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003; 44(8): 1003-13[PubMed]
21.
Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2002; 24(3): 332-7[PubMed]
22.
Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol. 1986; 43: 629-43[PubMed]
23.
Mallucci GR,
Nowack A,
Malarkey EB,
Yao J,
Bleckert A,
Hill J,
et al.
Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A. PLoS ONE. 2011; 6(12)[DOI]
24.
Sankar R. GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam. CNS Drugs. 2012; 26(3): 229-44[DOI]
25.
Tapalaga D, Suciu A, Schvartz M, Duca S. [The mechanism of action of phenobarbital on the metabolism of 131J-B.S.P. in cholestasis induced by ANIT in isolated and perfused rat liver (author's transl)]. Dtsch Z Verdau Stoffwechselkr. 1979; 39(5): 233-7[PubMed]
26.
Holder JL Jr, Wilfong AA. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2011; 12(16): 2573-81[DOI][PubMed]
27.
Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009; 23(2): 121-37[DOI][PubMed]
28.
Onuma T. [Cognitive dysfunction and antiepileptic drugs]. Brain Nerve. 2011; 63(4): 379-83[PubMed]
29.
Semah F, Thomas P, Coulbaut S, Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disord. 2014; [DOI][PubMed]
31.
Witt J, Elger CE, Helmstaedter C. Which drug-induced side effects would be tolerated in the prospect of seizure control? Epilepsy Behav. 2013; 29(1): 141-3[DOI]
32.
Poduri A, Sheidley BR, Shostak S, Ottman R. Genetic testing in the epilepsies—developments and dilemmas. Nat Rev Neurol. 2014; 10(5): 293-9[DOI]
33.
French JA, Gazzola DM. Antiepileptic drug treatment: new drugs and new strategies. Continuum (Minneap Minn). 2013; 19(3 Epilepsy): 643-55[DOI][PubMed]
34.
Yi Y, Lee JH, Suh ES. Toxic epidermal necrolysis induced by lamotrigine treatment in a child. Korean J Pedi. 2014; 57(3): 153[DOI]
35.
Sarangi SC, Tripathi M, Kakkar AK, Gupta YK. Effect of antiepileptic therapy on trace elements status in Indian population in a tertiary care hospital from northern India: A cross sectional study. Epilepsy Res. 2014; 108(5): 917-27[DOI][PubMed]
36.
Li M,
Tan J,
Yang X,
Su L,
Xie J,
Liang B,
et al.
The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy Res. 2014; [DOI][PubMed]
37.
Satishchandra P, Santhosh N, Sinha S. Epilepsy: Indian perspective. Ann Indian Acad Neurol. 2014; 17(5): 3[DOI]
38.
Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013; 46(15): 1323-38[DOI][PubMed]
39.
Pegg EJ, Zaman F. Sodium valproate-related hyperammonaemic encephalopathy. Case Rep. 2014; 2014[DOI]
40.
Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not levetiracetam induce bone alterations in female mice. Can J Physiol Pharmacol. 2014; [DOI][PubMed]
41.
Shingade PU, Wankhede V, Kataria PS, Sonone N. Rare case of phenytoin induced acute generalized exanthematous pustulosis with cerebellar syndrome. Indian J Dermatol. 2014; 59(2): 210[DOI][PubMed]
42.
Błaszczyk B, Szpringer M, Czuczwar SJ, Lasoń W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacoll Rep. 2013; 65(2): 399-409[DOI]
43.
Bourgeois BF. Initiating antiepileptic drug treatment and characteristics of drugs. Handb Clin Neurol. 2013; 111: 719-25[DOI][PubMed]
44.
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21): 2211-21[DOI][PubMed]
45.
Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995; 29(6): 619-24[PubMed]
46.
Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003; 348(6): 529-37[DOI][PubMed]
47.
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001; 286(18): 2270-9[PubMed]
48.
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2): 229-43[DOI][PubMed]
Readers' Comments